Spyre Therapeutics (SYRE) Retained Earnings (2015 - 2026)
Spyre Therapeutics posted quarterly Retained Earnings of -$767000.0 for Q1 2026, up 99.92% year-on-year from -$383644.6 in Q1 2025, and down 188.26% on a QoQ basis from $869000.0 in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Retained Earnings data on file, last reported at -$767000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 99.92% year-over-year to -$767000.0; the trailing twelve-month figure through Mar 2026 stood at -$767000.0 (up 99.92% YoY), and the FY2025 full-year result was $869000.0, up 100.09% from the prior year.
- Retained Earnings for Q1 2026 stood at -$767000.0, down from $869000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $869000.0 in Q4 2025 and bottomed at -$1.1 billion in Q2 2025.
- The 5-year median for Retained Earnings is -$444.0 million (2023), against an average of -$504.8 million.
- The widest annual swing landed in 2023, when Retained Earnings surged 729.17%; it then tumbled 322097.35% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$48000.0 in 2022, then surged by 729.17% to $302000.0 in 2023, then sank by 322097.35% to -$972.4 million in 2024, then jumped by 100.09% to $869000.0 in 2025, then slumped by 188.26% to -$767000.0 in 2026.
- The last three Retained Earnings figures came in at -$767000.0 (Q1 2026), $869000.0 (Q4 2025), and $791000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | -767,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -767,000.00 |
| Dec 31, 2025 | 869,000.00 |
| Sep 30, 2025 | 791,000.00 |
| Jun 30, 2025 | -1.05 Bn |
| Mar 31, 2025 | -1.02 Bn |
| Dec 31, 2024 | -972.43 Mn |
| Sep 30, 2024 | -916.14 Mn |
| Jun 30, 2024 | -847.10 Mn |
| Mar 31, 2024 | -808.27 Mn |
| Dec 31, 2023 | 302,000.00 |
| Sep 30, 2023 | -701.23 Mn |
| Jun 30, 2023 | -661.13 Mn |
| Mar 31, 2023 | -444.00 Mn |
| Dec 31, 2022 | -48,000.00 |
| Sep 30, 2022 | -406.80 Mn |
| Jun 30, 2022 | -388.57 Mn |
| Mar 31, 2022 | -366.25 Mn |
| Dec 31, 2021 | -341.81 Mn |
| Sep 30, 2021 | -321.40 Mn |
| Jun 30, 2021 | -301.06 Mn |
| Mar 31, 2021 | -294.23 Mn |
| Dec 31, 2020 | 11,000.00 |
| Sep 30, 2020 | -253.29 Mn |
| Jun 30, 2020 | -235.30 Mn |
| Mar 31, 2020 | -213.80 Mn |
| Dec 31, 2019 | 51,000.00 |
| Sep 30, 2019 | -173.60 Mn |
| Jun 30, 2019 | -152.05 Mn |
| Mar 31, 2019 | -134.03 Mn |
| Dec 31, 2018 | -27,000.00 |
| Sep 30, 2018 | -101.96 Mn |
| Jun 30, 2018 | -90.05 Mn |
| Mar 31, 2018 | -98,000.00 |
| Dec 31, 2017 | -102,000.00 |
| Sep 30, 2017 | -32,000.00 |
| Jun 30, 2017 | -58.16 Mn |
| Mar 31, 2017 | -37,000.00 |
| Dec 31, 2016 | -4,000.00 |
| Sep 30, 2016 | 3,000.00 |
| Jun 30, 2016 | 1,000.00 |
| Mar 31, 2016 | 3,000.00 |
| Dec 31, 2015 | -23.58 Mn |